Endpoints News 16. Dez. 2025 DBV charts new path to market peanut allergy patch after Phase 3 success
Endpoints News 16. Dez. 2025 Makary walks back talk of Covid-19 vaccine risk amid internal FDA debate
Endpoints News 16. Dez. 2025 Nektar's immunology drug misses in Phase 2b, execs cite enrollment errors
Endpoints News 16. Dez. 2025 J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell
Endpoints News 16. Dez. 2025 OrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Endpoints News 16. Dez. 2025 Chronic pain biotech Ambros Therapeutics emerges with $125M and Vivek Ramaswamy on board
Endpoints News 16. Dez. 2025 Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesity
Endpoints News 15. Dez. 2025 FDA wants to use more real-world data and calls again for early-phase trials reform
Endpoints News 15. Dez. 2025 Enhertu combo wins FDA approval for first-line use in metastatic breast cancer